Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr

The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI

This project will aim to develop a next-generation A3 adenosine receptor drug agonists

Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru

Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India

Pfizer posts Q3 loss as Covid-19 revenues shrink

Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter

Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs

Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months

Glenmark receives ANDA approval for Apremilast Tablets

Glenmark's current portfolio consists of 188 products authorized for distribution in the US

Ichnos Sciences inks agreement with Astria Therapeutics for OX40 antagonist monoclonal antibody portfolio

Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications